Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased

Alkermes (ALKS) Shares Outstanding (2016 - 2026)

Alkermes has reported Shares Outstanding over the past 16 years, most recently at $181.0 million for Q4 2025.

Quarterly Shares Outstanding rose 2.46% to $181.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $181.0 million through Dec 2025, up 2.46% year-over-year, with the annual reading at $181.0 million for FY2025, 2.46% up from the prior year.
Shares Outstanding was $181.0 million for Q4 2025 at Alkermes, roughly flat from $180.5 million in the prior quarter.
Over five years, Shares Outstanding peaked at $181.0 million in Q4 2025 and troughed at -$5.5 million in Q3 2023.
The 5-year median for Shares Outstanding is $171.7 million (2023), against an average of $129.5 million.
Year-over-year, Shares Outstanding crashed 102.31% in 2021 and then skyrocketed 4711.01% in 2022.
A 5-year view of Shares Outstanding shows it stood at $165.8 million in 2021, then grew by 1.91% to $169.0 million in 2022, then rose by 2.14% to $172.6 million in 2023, then rose by 2.38% to $176.7 million in 2024, then increased by 2.46% to $181.0 million in 2025.
Per Business Quant, the three most recent readings for ALKS's Shares Outstanding are $181.0 million (Q4 2025), $180.5 million (Q3 2025), and $180.4 million (Q2 2025).